Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

08.01.2020 | short review | Ausgabe 1/2020 Open Access

memo - Magazine of European Medical Oncology 1/2020

Cutaneous squamous cell carcinoma

Risk factors and new systemic treatment options in advanced disease

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2020
Autoren:
Magdalena Seidl-Philipp, Van Anh Nguyen
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Cutaneous squamous cell carcinoma (cSCC) accounts for approximately 20% of all skin cancers and is after basal cell carcinoma (BCC) the second most frequent form of nonmelanoma skin cancer (NMSC) [ 1]. The incidence of NMSC continues to rise since 1960 [ 2] and represents a major challenge for healthcare systems [ 3].
CSCC occurs predominantly on sun-exposed skin sites and is associated with high cumulative UV doses [ 4]. Phenotypic traits to develop cSCC are light hair, skin and eye colour [ 4]. Further major risk factors include older age [ 4] and immunosuppression [ 5]. It has been shown that white transplant recipients have a 65-fold higher risk of cSCC compared with the nontransplanted population [ 5]. The risk of developing cSCC is also increased in patients suffering from human immunodeficiency virus infection (HIV) and haematological diseases like non-Hodgkin lymphoma and chronic lymphatic leukaemia [ 4].
In most cases cSCC has a good prognosis and is curable by surgical resection. Nevertheless, a small percentage of patients progress to locally advanced or to metastasizing carcinoma [ 6]. A metastatic rate of 1.9–2.6% has been reported [ 7]. Regional lymph nodes are affected in approximately 85% of all cases, whereas the lungs, liver, brain and bones are less common sites of metastasis. The 10-year survival rates fall to less than 20% in case of locoregional lymph node metastases and less than 10% in the presence of distant metastases [ 6].
Risk factors for developing advanced cSCC are summarized in Table  1. Especially long-lasting and intense immunosuppression can induce rapid tumour growth and increase the probability for local recurrence and metastatic spread [ 8, 9]. Other risk factors associated with poor outcome have been identified, including large tumour diameter, lesion thickness, poor histological differentiation, location on the ear or lip and perineural involvement [ 4, 10].
Table 1
Risk factors for developing advanced cSCC
High-risk factors in cSCC
Tumour size (diameter) >2 cm
Depth of invasion ≥6 mm
Tumour site on ear, lip or areas of long-lasting chronic ulcers or inflammation
Acantholytic, spindle cell or desmoplastic histological subtype
Perineural involvement
Host immunosuppression
Recurrent lesions
Adapted from [ 4] and [ 10]
There is no recommended standard therapeutic regimen for advanced cSCC and the number of randomized controlled trials are limited [ 10]. Radiotherapy ± chemotherapy is considered as a conventional option for locally or regionally advanced disease [ 1012]. Systemic chemotherapy and EGFR-targeted therapy are traditionally applied in patients with distant metastasis [ 10]. The use of chemotherapy has been explored mainly through retrospective studies and case series [ 10]. Reported overall response rates (ORR) with platinum monotherapy ranged from 17% to 78%, albeit these responses were typically short-lived and overall survival was not substantially extended [ 13]. ORR higher than 80% have been reported to polychemotherapy with cisplatin in combination with 5‑fluourouracil and/or bleomycin [ 13, 14], but these results were only transient and not confirmed by subsequent studies [ 10]. Moreover, the toxicity profile of polychemotherapy precludes its use in a largely geriatric patient population with pre-existing comorbidities [ 10]. The EGFR-inhibitor cetuximab is preferentially used as subsequent line treatment when chemotherapy is unfeasible or there is a progressive disease [ 10]. In a phase II clinical trial cetuximab showed an ORR of 28% and a median progression-free survival (PFS) of 4.1 months with less toxicity in patients with locally advanced and metastatic cSCC [ 15]. In smaller studies higher ORR could be achieved when combined with chemotherapy and/or radiotherapy. Yet, median PFS remained still short in most cases [ 16].
Recently, data of 190 unselected patients with advanced cSCC who were diagnosed between 2010 and 2011 in Germany and Austria were analysed retrospectively with regard to patient profiles and treatment patterns, thus reflecting real-life conditions. In all, 40% of the patients suffered from locally advanced and 60% from metastatic cSCC. Only 32 patients, 3 with locally advanced and 29 with metastatic cSCC, were treated with systemic antitumour regimens, in most cases with EGFR-inhibitor based therapies. ORR was 26% and median duration of response was 5 months [ 17]. These data confirm that chemotherapy and EGFR-targeted therapy offer only modest clinical benefit. Hence, there is a critical unmet need for improved advanced cSSC treatment. Checkpoint immunotherapy represents a promising new treatment option for inoperable cSCC.

PD1-based immunotherapy—a new systemic treatment option in advanced cSCC

The blocking of the PD1/PD-L1 pathway can enhance T‑cell-activity and consequently promote tumour immunosurveillance [ 18]. In the last few years, the checkpoint inhibitors have been highly discussed as a promising treatment option for patients with advanced cSCC. The critical role of the immune system in controlling the development and growth of cSCC is well-known as cSSC diagnosed in immunosuppressed organ transplant recipients is more likely to show unfavourable prognostic features and to metastasize [ 5, 8]. Furthermore, findings such as high UV-mutation burden, infiltration with lymphocytes and PD-L1 expression in high-risk disease strongly indicate that targeting the immune system with PD‑1 inhibitors could be effective in advanced cSSC [ 1921].
The first case reports documenting the efficacy of the PD‑1 inhibitors pembrolizumab and cemiplimab in advanced cSCC were published in 2016 [ 22, 23]. In September 2018, the PD‑1 inhibitor cemiplimab became the first FDA-approved systemic drug for patients with locally advanced or metastatic cSCC who are not candidates for curative surgery or radiation [ 24]. Approval in Europe followed in July 2019. The approval was based on the results of a combined phase I/II clinical trial involving 85 patients, 75 with metastatic disease and 8 with locally advanced disease [ 25]. Most had undergone previous treatments, including prior radiation therapy and chemotherapy. 81% of pretreatment tumour samples were positive for PD-L1 expression. The results showed a quick onset of the clinical response after about 2 months with an ORR of 50% and a durable disease control rate (DCR) of 65.4%. A partial response (PR) was observed in 24 patients and a complete response (CR) in 4 patients. Similar efficacy was observed in patients with regional metastatic disease and in those with distant metastatic disease. The ORR was clearly associated with the status of prior systemic treatments: patients without prior systemic treatment had an ORR close to 60% and those with prior systemic treatment had an ORR close to 40%. The median duration of response (DOR) had not been reached and the estimated PFS probability at 1 year was 53%, whereas the probability of survival at 1 year was more than 80%. Most of the adverse events related to treatment were grade 1 or 2. Serious adverse effects accounted for less than 10%. The most common adverse events of any grade were diarrhoea (27%), fatigue (24%), nausea (17%), constipation (15%) and rash (15%). There were 4 reported deaths due to adverse events. Of note, none were immune-related. Despite the advanced age of the patients (median age of patients over 70 years) no new safety signals were reported [ 25], suggesting that high age does not influence the efficacy and safety of the immunotherapy although patients enrolled in clinical trials have usually a better performance status compared with real-world patients.
The importance of PD‑1 inhibitors has been further supported by preliminary data of a phase II trial with pembrolizumab on 39 patients, naive of chemotherapy and of EGFR inhibitors, with unresectable and/or metastatic cSCC and a median age of 80 showing an ORR of 42% and a median PFS of 7 months. Baseline PD-L1 expression was positive in 58%. Reported adverse events were consistent with previous studies. There were no severe adverse events or immune-related deaths [ 26].
Great interest currently exists in ongoing clinical trials evaluating the efficacy of immune checkpoint inhibitors in unresectable cSCC, especially in combination with other treatment modalities [ 27], (Table  2). PD1 inhibitors are also tested in the adjuvant and neoadjuvant setting. Two phase III and one phase II clinical trial are evaluating adjuvant cemiplimab and pembrolizumab following surgery and radiation in patients with high-risk locally advanced cSCC (NCT03969004, NCT03833167, NCT03057613). The application of neoadjuvant cemiplimab is being investigated in a phase II clinical trial in patients with advanced resectable cSCC of the head and neck followed by definitive local surgery and radiation (NCT03565783) [ 27].
Table 2
PD-1/PD-L1 based immunotherapy in advanced cSCC—ongoing clinical trials as listed on ClinicalTrials.gov [ 27]
NCT identifier
Study title
Phase
Status
Cancer type
Drug
NCT02760498
Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma
Phase 2
Recruiting
Advanced cSCC
Cemiplimab
NCT02964559
Pembrolizumab in patients with locally advanced or metastatic skin cancer
Phase 2
Recruiting
Advanced cSCC
Pembrolizumab
NCT03284424
Study of pembrolizumab (MK-3475) in adults with recurrent/metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced unresectable cSCC (MK-3475-629/KEYNOTE-629)
Phase 2
Active, not recruiting
Advanced cSCC
Pembrolizumab
NCT03834233
Nivolumab in patients with advanced cutaneous squamous cell carcinoma (CA209-9JC)
Phase 2
Recruiting
Advanced cSCC
Nivolumab
NCT03737721
The UNSCARRed study: unresectable squamous cell carcinoma treated with avelumab and radical radiotherapy (UNSCARRed)
Phase 2
Recruiting
Unresectable cSCC
Avelumab with radical radiotherapy
NCT03944941
Avelumab with or without cetuximab in treating patients with advanced skin squamous cell cancer
Phase 2
Recruiting
Metastatic cSCC
Avelumab, Cetuximab
NCT03082534
Pembrolizumab combined with cetuximab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Phase 2
Recruiting
Advanced HNSCC and cSCC
Pembrolizumab, Cetuximab
NCT03666325
Immunotherapy ± EGFR inhibitor in advanced/metastatic cSCC: tackling primary and secondary resistance (I-Tackle)
Phase 2
Not yet recruiting
Advanced cSCC
Pembrolizumab, Cetuximab
NCT04050436
Study evaluating cemiplimab alone and combined with RP1 in treating advanced squamous skin cancer (CERPASS)
Phase 2
Recruiting
Advanced cSCC
Cemiplimab, RP1 (genetically modified herpes simplex type 1 virus)
NCT03901573
High-risk skin cancers with atezolizumab plus NT-I7
Phase 1/2
Not yet recruiting
Advanced cSCC and others
Atezolizumab + NT-I7 (recombinant human IL-7-hybrid Fc)
NCT03684785
Intratumoral AST-008 combined with pembrolizumab in patients with advanced solid tumours
Phase 1b/2
Recruiting
Advanced cSCC and others
AST-008 (TLR9 agonist SNA), Pembrolizumab
NCT02955290
CIMAvax vaccine, nivolumab, and pembrolizumab in treating patients with advanced non-small cell lung cancer or squamous head and neck cancer
Phase 1/2
Recruiting
Advanced cSCC of the head and neck and others
Recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and Nivolumab or Pembrolizumab
NCT03871348
A first-in-human dose escalation and expansion study to evaluate intratumoural administration of SAR441000 as monotherapy and in combination with cemiplimab in patients with advanced solid tumours
Phase 1
Recruiting
Advanced cSCC and others
SAR441000, Cemiplimab
NCT03590054
A phase 1b dose escalation/expansion study of abexinostat in combination with pembrolizumab in patients with advanced solid tumour malignancies
Phase 1b/2
Recruiting
Advanced cSCC of the head and neck and others
Abexinostat, Pembrolizumab
NCT03773744
MG1-MAGEA3 with Ad-MAGEA3 and pembrolizumab in patients with previously treated metastatic melanoma or cutaneous squamous cell carcinoma (Pelican)
Phase 1
Not yet recruiting
Metastatic cSCC and others
Ad-MAGEA3, MG-1MAGEA3, Pembrolizumab, Cyclophosphamide
NCT04007744
Sonidegib and pembrolizumab in treating patients with advanced solid tumours
Phase 1
Not yet recruiting
Advanced cSCC of the head and neck and others
Sonidegib, Pembrolizumab
NCT03108131
Cobimetinib and atezolizumab in treating participants with advanced or refractory rare tumours
Phase 2
Recruiting
Advanced cSCC and others
Cobimetinib, Atezolizumab
NCT03565783
Cemiplimab in treating participants with recurrent stage III-IV head and neck squamous cell cancer before surgery
Phase 2
Recruiting
Advanced cSCC of the head and neck and HNSCC (neoadjuvant)
Cemiplimab
NCT03969004
Study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma
Phase 3
Recruiting
High-risk cSCC (adjuvant)
Cemiplimab, Placebo
NCT03833167
Pembrolizumab versus placebo following surgery and radiation in participants with locally advanced cutaneous squamous cell carcinoma (MK-3475-630/KEYNOTE-630)
Phase 3
Recruiting
Locally advanced cSSC (adjuvant)
Pembrolizumab
NCT03057613
The addition of pembrolizumab to postoperative radiotherapy in cutaneous squamous cell cancer of the head and neck
Phase 2
Recruiting
High-risk cSCC of the head and neck (adjuvant)
Pembrolizumab
NCT03816332
Tacrolimus, nivolumab, and ipilimumab in treating kidney transplant recipients with selected unresectable or metastatic cancers
Phase 1
Recruiting
Metastatic cSCC and others
Nivolumab, Ipilimumab, Prednisolon, Tacrolimus
As mentioned, organ transplant recipients are much more likely to develop cSSC than the general population [ 5]. Unfortunately, data regarding safety and efficacy of immune checkpoint inhibitors in this population are lacking. Routinely, those patients are excluded from immunotherapy trials due to safety concerns. There is emerging evidence that these agents may lead to graft rejection although there are reports in which immune checkpoint inhibitors have been used without resulting in organ rejection [ 28, 29]. A recent review, which included 57 organ transplant recipients receiving immune checkpoint inhibitors, reported graft rejection in 37% of patients and death due to graft rejection in 14% [ 30]. Most deaths (51%) were related to progression of malignancy. The highest rejection rate was seen in patients with kidney transplants (40.1%), followed by liver (35%) and heart (20%) transplants. Interestingly, 52% of patients receiving nivolumab experienced graft rejection, in contrast with 25% receiving ipilimumab and 26.7% receiving pembrolizumab. Time from transplantation and choice of immunosuppression at the time of treatment with immunotherapy might be important factors for the outcome [ 30]. Another study, presenting the largest single-centre cohort of organ transplant recipients being treated with checkpoint inhibitor therapy, reported graft rejection in 41% and death primarily from allograft rejection or rejection complications in 46% of patients. The median time to rejection was 21 days and rejection rates were similar for anti-CTLA‑4 and anti-PD‑1 therapy. Also, no association was observed between time since organ transplantation and frequency, timing or type of rejection [ 31]. These data indicate that further studies are clearly needed to delineate a subset of organ transplant recipients who might benefit from immunotherapy. In this respect, a phase I clinical trial is examining kidney transplant recipients with selected unresectable cancers including cSCC who are treated with tacrolimus, nivolumab and ipilimumab (NCT03816332) [ 27].
Take home message
A new era in the treatment of advanced cSCC has been paved by the approval of the PD‑1 inhibitors cemiplimab and pembrolizumab. Clinical studies with PD‑1 inhibitors led to dramatically improved outcomes in many immunocompetent cSCC patients. Questions to be answered in the coming years will be whether response rates can be further improved by combination therapies and whether PD1 inhibitors are also effective in the adjuvant and neoadjuvant setting. Additional critical questions include the usage of immune checkpoint inhibitors in immunocompromised cSCC patients who have the highest medical need for new therapeutic options.

Conflict of interest

M. Seidl-Philipp reports financial support from BMS outside the submitted work. V.A. Nguyen reports speaker’s honoraria and consultancy fees from Bristol-Myers Squibb and Merck Sharp & Dohme outside the submitted work.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020 Zur Ausgabe